Self-assembled nanoscale coordination polymers with trigger release properties for effective anticancer therapy

被引:219
作者
Liu, Demin [1 ]
Poon, Christopher [1 ]
Lu, Kuangda [1 ]
He, Chunbai [1 ]
Lin, Wenbin [1 ]
机构
[1] Univ Chicago, Dept Chem, Chicago, IL 60637 USA
关键词
TARGETED DELIVERY; DRUG-DELIVERY; CANCER-CELLS; PRECLINICAL EFFICACY; LIPOSOMAL-CISPLATIN; CONTRAST AGENTS; PHASE-III; TUMOR; PLATINUM; NANOPARTICLES;
D O I
10.1038/ncomms5182
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Nanoscale coordination polymers (NCPs) are self-assembled from metal ions and organic bridging ligands, and can overcome many drawbacks of existing drug delivery systems by virtue of tunable compositions, sizes and shapes, high drug loadings, ease of surface modification and intrinsic biodegradability. Here we report the self-assembly of zinc bisphosphonate NCPs that carry 48 +/- 3 wt% cisplatin prodrug and 45 +/- 5 wt% oxaliplatin prodrug. In vivo pharmacokinetic studies in mice show minimal uptake of pegylated NCPs by the mononuclear phagocyte system and excellent blood circulation half-lives of 16.4 +/- 2.9 and 12.0 +/- 3.9 h for the NCPs carrying cisplatin and oxaliplatin, respectively. In all tumour xenograft models evaluated, including CT26 colon cancer, H460 lung cancer and AsPC-1 pancreatic cancer, pegylated NCPs show superior potency and efficacy compared with free drugs. As the first example of using NCPs as nanotherapeutics with enhanced antitumour activities, this study establishes NCPs as a promising drug delivery platform for cancer therapy.
引用
收藏
页数:11
相关论文
共 69 条
[1]   Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study [J].
Alberts, SR ;
Townley, PM ;
Goldberg, RM ;
Cha, SS ;
Sargent, DJ ;
Moore, DF ;
Krook, JE ;
Pitot, HC ;
Fitch, TR ;
Wiesenfeld, M ;
Mailliard, JA .
ANNALS OF ONCOLOGY, 2003, 14 (04) :580-585
[2]   Factors affecting the clearance and biodistribution of polymeric nanoparticles [J].
Alexis, Frank ;
Pridgen, Eric ;
Molnar, Linda K. ;
Farokhzad, Omid C. .
MOLECULAR PHARMACEUTICS, 2008, 5 (04) :505-515
[3]   Liposomal drug delivery systems: From concept to clinical applications [J].
Allen, Theresa M. ;
Cullis, Pieter R. .
ADVANCED DRUG DELIVERY REVIEWS, 2013, 65 (01) :36-48
[4]   Advanced strategies in liposomal cancer therapy: Problems and prospects of active and tumor specific drug release [J].
Andresen, TL ;
Jensen, SS ;
Jorgensen, K .
PROGRESS IN LIPID RESEARCH, 2005, 44 (01) :68-97
[5]  
Ashley CE, 2011, NAT MATER, V10, P389, DOI [10.1038/NMAT2992, 10.1038/nmat2992]
[6]   In depth analysis of the in vivo toxicity of nanoparticles of porous iron(III) metal-organic frameworks [J].
Baati, Tarek ;
Njim, Leila ;
Neffati, Fadoua ;
Kerkeni, Abdelhamid ;
Bouttemi, Muriel ;
Gref, Ruxandra ;
Najjar, Mohamed Fadhel ;
Zakhama, Abdelfateh ;
Couvreur, Patrick ;
Serre, Christian ;
Horcajada, Patricia .
CHEMICAL SCIENCE, 2013, 4 (04) :1597-1607
[7]   Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in mouse tumor models [J].
Bandak, S ;
Goren, D ;
Horowitz, A ;
Tzemach, D ;
Gabizon, A .
ANTI-CANCER DRUGS, 1999, 10 (10) :911-920
[8]   Doxil® - The first FDA-approved nano-drug: Lessons learned [J].
Barenholz, Yechezkel .
JOURNAL OF CONTROLLED RELEASE, 2012, 160 (02) :117-134
[9]   About dendrimers: Structure, physical properties, and applications [J].
Bosman, AW ;
Janssen, HM ;
Meijer, EW .
CHEMICAL REVIEWS, 1999, 99 (07) :1665-1688
[10]   Clinical overview on Lipoplatin™: a successful liposomal formulation of cisplatin [J].
Boulikas, Teni .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (08) :1197-1218